O	0	7	VEGF165	VEGF165	NN	B-NP
O	8	17	expressed	express	VBN	B-VP
O	18	20	by	by	IN	B-PP
O	21	22	a	a	DT	B-NP
O	23	34	replication	replication	NN	I-NP
O	34	35	-	-	HYPH	B-NP
O	35	44	deficient	deficient	JJ	I-NP
O	45	56	recombinant	recombinant	JJ	I-NP
O	57	67	adenovirus	adenovirus	NN	I-NP
O	68	74	vector	vector	NN	I-NP
O	75	82	induces	induce	VBZ	B-VP
O	83	95	angiogenesis	angiogenesis	NN	B-NP
O	96	98	in	in	FW	B-ADVP
O	99	103	vivo	vivo	FW	I-ADVP
O	103	104	.	.	.	O

O	105	107	To	To	TO	B-VP
O	108	116	evaluate	evaluate	VB	I-VP
O	117	120	the	the	DT	B-NP
O	121	128	concept	concept	NN	I-NP
O	129	133	that	that	IN	B-SBAR
O	134	143	localized	localize	VBN	B-NP
O	144	152	delivery	delivery	NN	I-NP
O	153	155	of	of	IN	B-PP
O	156	166	angiogenic	angiogenic	JJ	B-NP
O	167	174	factors	factor	NNS	I-NP
O	175	178	via	via	IN	B-PP
O	179	184	virus	virus	NN	B-NP
O	184	185	-	-	HYPH	B-NP
O	185	193	mediated	mediate	VBN	I-NP
O	194	198	gene	gene	NN	I-NP
O	199	207	transfer	transfer	NN	I-NP
O	208	211	may	may	MD	B-VP
O	212	214	be	be	VB	I-VP
O	215	221	useful	useful	JJ	B-ADJP
O	222	224	in	in	IN	B-PP
O	225	228	the	the	DT	B-NP
O	229	238	treatment	treatment	NN	I-NP
O	239	241	of	of	IN	B-PP
O	242	250	ischemic	ischemic	JJ	B-NP
O	251	260	disorders	disorder	NNS	I-NP
O	260	261	,	,	,	O
O	262	265	the	the	DT	B-NP
O	266	277	replication	replication	NN	I-NP
O	277	278	-	-	HYPH	B-NP
O	278	287	deficient	deficient	JJ	I-NP
O	288	298	adenovirus	adenovirus	NN	I-NP
O	299	300	(	(	(	O
O	300	302	Ad	Ad	NN	B-NP
O	302	303	)	)	)	O
O	304	310	vector	vector	NN	B-NP
O	311	316	AdCMV	AdCMV	NN	I-NP
O	316	317	.	.	.	B-NP
O	317	324	VEGF165	VEGF165	NN	I-NP
O	325	326	(	(	(	O
O	326	331	where	where	WRB	B-ADVP
O	332	335	CMV	CMV	NN	B-NP
O	336	338	is	be	VBZ	B-VP
O	339	354	cytomegalovirus	cytomegalovirus	NN	B-NP
O	355	358	and	and	CC	I-NP
O	359	363	VEGF	VEGF	NN	I-NP
O	364	366	is	be	VBZ	B-VP
O	367	375	vascular	vascular	JJ	B-NP
O	376	387	endothelial	endothelial	JJ	I-NP
O	388	394	growth	growth	NN	I-NP
O	395	401	factor	factor	NN	I-NP
O	401	402	)	)	)	O
O	403	413	containing	contain	VBG	B-VP
O	414	417	the	the	DT	B-NP
O	418	422	cDNA	cDNA	NN	I-NP
O	423	426	for	for	IN	B-PP
O	427	432	human	human	JJ	B-NP
O	433	440	VEGF165	VEGF165	NN	I-NP
O	440	441	,	,	,	O
O	442	443	a	a	DT	B-NP
O	444	452	secreted	secrete	VBN	I-NP
B-Cell	453	464	endothelial	endothelial	JJ	I-NP
I-Cell	465	469	cell	cell	NN	I-NP
O	469	470	-	-	HYPH	B-NP
O	470	478	specific	specific	JJ	I-NP
O	479	489	angiogenic	angiogenic	JJ	I-NP
O	490	496	growth	growth	NN	I-NP
O	497	503	factor	factor	NN	I-NP
O	503	504	,	,	,	O
O	505	508	was	be	VBD	B-VP
O	509	520	constructed	construct	VBN	I-VP
O	520	521	.	.	.	O

B-Cell	522	527	Human	Human	JJ	B-NP
I-Cell	528	537	umbilical	umbilical	JJ	I-NP
I-Cell	538	542	vein	vein	NN	I-NP
I-Cell	543	554	endothelial	endothelial	JJ	I-NP
I-Cell	555	560	cells	cell	NNS	I-NP
O	561	562	(	(	(	O
B-Cell	562	568	HUVECs	HUVEC	NNS	B-NP
O	568	569	)	)	)	O
O	570	573	and	and	CC	O
B-Cell	574	577	rat	rat	NN	B-NP
I-Cell	578	583	aorta	aorta	NN	I-NP
I-Cell	584	590	smooth	smooth	JJ	I-NP
I-Cell	591	597	muscle	muscle	NN	I-NP
I-Cell	598	603	cells	cell	NNS	I-NP
O	604	605	(	(	(	O
B-Cell	605	611	RASMCs	RASMC	NNS	B-NP
O	611	612	)	)	)	O
O	613	621	infected	infect	VBN	B-VP
O	622	626	with	with	IN	B-PP
O	627	632	AdCMV	AdCMV	NN	B-NP
O	632	633	.	.	.	O
O	633	640	VEGF165	VEGF165	NN	B-NP
O	641	642	(	(	(	O
O	642	643	5	5	CD	B-NP
O	644	647	and	and	CC	I-NP
O	648	650	20	20	CD	I-NP
O	651	657	plaque	plaque	NN	I-NP
O	657	658	-	-	HYPH	O
O	658	665	forming	form	VBG	B-VP
O	666	671	units	unit	NNS	B-NP
O	672	673	[	[	(	O
O	673	676	pfu	pfu	NN	B-NP
O	676	677	]	]	)	O
O	678	681	per	per	IN	B-PP
B-Cell	682	686	cell	cell	NN	B-NP
O	686	687	)	)	)	O
O	688	700	demonstrated	demonstrate	VBD	B-VP
O	701	705	VEGF	VEGF	NN	B-NP
O	706	710	mRNA	mRNA	NN	I-NP
O	711	721	expression	expression	NN	I-NP
O	722	725	and	and	CC	O
O	726	733	protein	protein	NN	B-NP
O	734	743	secretion	secretion	NN	I-NP
O	744	748	into	into	IN	B-PP
O	749	752	the	the	DT	B-NP
B-Organism_substance	753	764	supernatant	supernatant	NN	I-NP
O	764	765	.	.	.	O

O	766	777	Furthermore	Furthermore	RB	B-ADVP
O	777	778	,	,	,	O
O	779	782	the	the	DT	B-NP
O	783	794	conditioned	condition	VBN	I-NP
O	795	801	medium	medium	NN	I-NP
O	802	806	from	from	IN	B-PP
O	807	812	these	these	DT	B-NP
B-Cell	813	818	cells	cell	NNS	I-NP
O	819	827	enhanced	enhance	VBD	B-VP
B-Multi-tissue_structure	828	836	vascular	vascular	JJ	B-NP
O	837	849	permeability	permeability	NN	I-NP
O	850	852	in	in	FW	B-ADVP
O	853	857	vivo	vivo	FW	I-ADVP
O	857	858	.	.	.	O

O	859	861	In	In	IN	B-PP
O	862	870	contrast	contrast	NN	B-NP
O	870	871	,	,	,	O
O	872	879	neither	neither	CC	O
O	880	884	VEGF	VEGF	NN	B-NP
O	885	889	mRNA	mRNA	NN	I-NP
O	890	893	nor	nor	CC	O
O	894	902	secreted	secrete	VBN	B-NP
O	903	910	protein	protein	NN	I-NP
O	911	914	was	be	VBD	B-VP
O	915	920	found	find	VBN	I-VP
O	921	923	in	in	IN	B-PP
O	924	934	uninfected	uninfected	JJ	B-NP
B-Cell	935	941	HUVECs	HUVEC	NNS	I-NP
O	942	944	or	or	CC	I-NP
B-Cell	945	951	RASMCs	RASMC	NNS	I-NP
O	952	954	or	or	CC	B-PP
O	955	957	in	in	IN	B-PP
B-Cell	958	963	cells	cell	NNS	B-NP
O	964	972	infected	infect	VBN	B-VP
O	973	977	with	with	IN	B-PP
O	978	981	the	the	DT	B-NP
O	982	989	control	control	NN	I-NP
O	990	996	vector	vector	NN	I-NP
O	997	1002	AdCMV	AdCMV	NN	I-NP
O	1002	1003	.	.	.	O
O	1003	1007	beta	beta	NN	B-NP
O	1008	1011	gal	gal	JJ	B-ADJP
O	1012	1013	(	(	(	O
O	1013	1018	where	where	WRB	B-ADVP
O	1019	1023	beta	beta	NN	B-NP
O	1024	1027	gal	gal	NN	I-NP
O	1028	1030	is	be	VBZ	B-VP
O	1031	1035	beta	beta	SYM	B-ADJP
O	1035	1036	-	-	HYPH	B-NP
O	1036	1049	galactosidase	galactosidase	NN	I-NP
O	1049	1050	)	)	)	O
O	1050	1051	.	.	.	O

O	1052	1062	Assessment	Assessment	NN	B-NP
O	1063	1065	of	of	IN	B-PP
O	1066	1073	starved	starve	VBN	B-NP
B-Cell	1074	1080	HUVECs	HUVEC	NNS	I-NP
O	1081	1083	at	at	IN	B-PP
O	1084	1086	14	14	CD	B-NP
O	1087	1091	days	day	NNS	I-NP
O	1092	1104	demonstrated	demonstrate	VBD	B-VP
O	1105	1112	sixfold	sixfold	RB	B-NP
O	1113	1117	more	more	JJR	I-NP
B-Cell	1118	1123	cells	cell	NNS	I-NP
O	1124	1127	for	for	IN	B-PP
O	1128	1133	AdCMV	AdCMV	NN	B-NP
O	1133	1134	.	.	.	O
O	1134	1141	VEGF165	VEGF165	NN	B-NP
O	1141	1142	-	-	HYPH	B-NP
O	1142	1150	infected	infect	VBN	I-NP
B-Cell	1151	1157	HUVECs	HUVEC	NNS	I-NP
O	1158	1159	(	(	(	O
O	1159	1161	20	20	CD	B-NP
O	1162	1165	pfu	pfu	NN	I-NP
O	1166	1169	per	per	IN	B-PP
B-Cell	1170	1174	cell	cell	NN	B-NP
O	1174	1175	)	)	)	O
O	1176	1180	than	than	IN	B-PP
O	1181	1184	for	for	IN	B-PP
O	1185	1191	either	either	CC	B-NP
O	1192	1200	infected	infected	JJ	I-NP
O	1201	1203	or	or	CC	I-NP
O	1204	1214	uninfected	uninfected	JJ	I-NP
O	1215	1222	control	control	NN	I-NP
B-Cell	1223	1228	cells	cell	NNS	I-NP
O	1228	1229	.	.	.	O

B-Cell	1230	1235	RASMC	RASMC	NN	B-NP
O	1236	1249	proliferation	proliferation	NN	I-NP
O	1250	1253	was	be	VBD	B-VP
O	1254	1264	unaffected	unaffected	JJ	B-ADJP
O	1265	1267	by	by	IN	B-PP
O	1268	1277	infection	infection	NN	B-NP
O	1278	1282	with	with	IN	B-PP
O	1283	1288	AdCMV	AdCMV	NN	B-NP
O	1288	1289	.	.	.	O
O	1289	1296	VEGF165	VEGF165	NN	B-NP
O	1296	1297	.	.	.	O

O	1298	1302	When	When	WRB	B-ADVP
O	1303	1309	plated	plat	VBN	B-VP
O	1310	1312	in	in	IN	B-PP
O	1313	1314	2	2	CD	B-NP
O	1314	1315	%	%	NN	I-NP
B-Organism_substance	1316	1321	serum	serum	NN	I-NP
O	1322	1324	on	on	IN	B-PP
O	1325	1331	dishes	dish	NNS	B-NP
O	1332	1341	precoated	precoate	VBN	B-VP
O	1342	1346	with	with	IN	B-PP
O	1347	1360	reconstituted	reconstitute	VBN	B-NP
B-Cellular_component	1361	1369	basement	basement	NN	I-NP
I-Cellular_component	1370	1378	membrane	membrane	NN	I-NP
O	1379	1380	(	(	(	O
O	1380	1388	Matrigel	Matrigel	NN	B-NP
O	1388	1389	)	)	)	O
O	1389	1390	,	,	,	O
B-Cell	1391	1397	HUVECs	HUVEC	NNS	B-NP
O	1398	1406	infected	infect	VBN	B-VP
O	1407	1411	with	with	IN	B-PP
O	1412	1417	AdCMV	AdCMV	NN	B-NP
O	1417	1418	.	.	.	O
O	1418	1425	VEGF165	VEGF165	NN	B-NP
O	1426	1427	(	(	(	O
O	1427	1429	20	20	CD	B-NP
O	1430	1433	pfu	pfu	NN	I-NP
O	1434	1437	per	per	IN	B-PP
B-Cell	1438	1442	cell	cell	NN	B-NP
O	1442	1443	)	)	)	O
O	1444	1458	differentiated	differentiate	VBN	B-VP
O	1459	1463	into	into	IN	B-PP
B-Tissue	1464	1473	capillary	capillary	JJ	B-NP
I-Tissue	1473	1474	-	-	HYPH	I-NP
I-Tissue	1474	1478	like	like	JJ	I-NP
I-Tissue	1479	1489	structures	structure	NNS	I-NP
O	1489	1490	.	.	.	O

O	1491	1496	Under	Under	IN	B-PP
O	1497	1504	similar	similar	JJ	B-NP
O	1505	1515	conditions	condition	NNS	I-NP
O	1515	1516	,	,	,	O
O	1517	1521	both	both	DT	B-NP
O	1522	1532	uninfected	uninfected	JJ	I-NP
B-Cell	1533	1539	HUVECs	HUVEC	NNS	I-NP
O	1540	1543	and	and	CC	I-NP
B-Cell	1544	1550	HUVECs	HUVEC	NNS	I-NP
O	1551	1559	infected	infect	VBN	B-VP
O	1560	1564	with	with	IN	B-PP
O	1565	1570	AdCMV	AdCMV	NN	B-NP
O	1570	1571	.	.	.	O
O	1571	1575	beta	beta	NN	B-NP
O	1576	1579	gal	gal	JJ	B-ADJP
O	1580	1583	did	do	VBD	B-VP
O	1584	1587	not	not	RB	I-VP
O	1588	1601	differentiate	differentiate	VB	I-VP
O	1601	1602	.	.	.	O

O	1603	1605	To	To	TO	B-VP
O	1606	1614	evaluate	evaluate	VB	I-VP
O	1615	1618	the	the	DT	B-NP
O	1619	1626	ability	ability	NN	I-NP
O	1627	1629	of	of	IN	B-PP
O	1630	1635	AdCMV	AdCMV	NN	B-NP
O	1635	1636	.	.	.	O
O	1636	1643	VEGF165	VEGF165	NN	B-NP
O	1644	1646	to	to	TO	B-VP
O	1647	1655	function	function	VB	I-VP
O	1656	1658	in	in	FW	B-ADVP
O	1659	1663	vivo	vivo	FW	I-ADVP
O	1663	1664	,	,	,	O
O	1665	1671	either	either	DT	B-NP
O	1672	1677	AdCMV	AdCMV	NN	I-NP
O	1677	1678	.	.	.	O

O	1679	1686	VEGF165	VEGF165	NN	B-NP
O	1687	1689	or	or	CC	I-NP
O	1690	1695	AdCMV	AdCMV	NN	I-NP
O	1695	1696	.	.	.	O
O	1696	1700	beta	beta	NN	B-NP
O	1701	1704	gal	gal	JJ	B-ADJP
O	1705	1706	(	(	(	O
O	1706	1707	2	2	CD	B-NP
O	1708	1709	x	x	CC	I-NP
O	1710	1712	10	10	CD	I-NP
O	1712	1713	(	(	(	O
O	1713	1715	10	10	CD	B-NP
O	1715	1716	)	)	)	O
O	1717	1720	pfu	pfu	NN	B-NP
O	1720	1721	)	)	)	O
O	1722	1725	was	be	VBD	B-VP
O	1726	1737	resuspended	resuspend	VBN	I-VP
O	1738	1740	in	in	IN	B-PP
O	1741	1742	0	0	CD	B-NP
O	1742	1743	.	.	.	O
O	1743	1744	5	5	CD	B-NP
O	1745	1747	mL	mL	NN	I-NP
O	1748	1756	Matrigel	Matrigel	NNP	I-NP
O	1757	1760	and	and	CC	O
O	1761	1769	injected	inject	VBN	B-VP
B-Immaterial_anatomical_entity	1770	1784	subcutaneously	subcutaneously	RB	B-ADVP
O	1785	1789	into	into	IN	B-PP
O	1790	1794	mice	mouse	NNS	B-NP
O	1794	1795	.	.	.	O

O	1796	1815	Immunohistochemical	Immunohistochemical	JJ	B-NP
O	1816	1824	staining	staining	NN	I-NP
O	1825	1837	demonstrated	demonstrate	VBD	B-VP
O	1838	1842	VEGF	VEGF	NN	B-NP
O	1843	1845	in	in	IN	B-PP
O	1846	1849	the	the	DT	B-NP
B-Tissue	1850	1857	tissues	tissue	NNS	I-NP
O	1858	1869	surrounding	surround	VBG	B-VP
O	1870	1873	the	the	DT	B-NP
O	1874	1882	Matrigel	Matrigel	NNP	I-NP
O	1883	1888	plugs	plug	NNS	I-NP
O	1889	1899	containing	contain	VBG	B-VP
O	1900	1905	AdCMV	AdCMV	NN	B-NP
O	1905	1906	.	.	.	O
O	1906	1913	VEGF165	VEGF165	NN	B-NP
O	1914	1916	up	up	RB	B-NP
O	1917	1919	to	to	TO	I-NP
O	1920	1921	3	3	CD	I-NP
O	1922	1927	weeks	week	NNS	I-NP
O	1928	1933	after	after	IN	B-PP
O	1934	1943	injection	injection	NN	B-NP
O	1943	1944	,	,	,	O
O	1945	1952	whereas	whereas	IN	O
O	1953	1955	no	no	DT	B-NP
O	1956	1960	VEGF	VEGF	NN	I-NP
O	1961	1964	was	be	VBD	B-VP
O	1965	1970	found	find	VBN	I-VP
O	1971	1973	in	in	IN	B-PP
O	1974	1977	the	the	DT	B-NP
O	1978	1985	control	control	NN	I-NP
O	1986	1991	plugs	plug	NNS	I-NP
O	1992	1996	with	with	IN	B-PP
O	1997	2002	AdCMV	AdCMV	NN	B-NP
O	2002	2003	.	.	.	O
O	2003	2007	beta	beta	NN	B-NP
O	2008	2011	gal	gal	JJ	B-ADJP
O	2011	2012	.	.	.	O

O	2013	2016	Two	Two	CD	B-NP
O	2017	2022	weeks	week	NNS	I-NP
O	2023	2028	after	after	IN	B-PP
O	2029	2038	injection	injection	NN	B-NP
O	2038	2039	,	,	,	O
O	2040	2045	there	there	EX	B-NP
O	2046	2049	was	be	VBD	B-VP
O	2050	2062	histological	histological	JJ	B-NP
O	2063	2071	evidence	evidence	NN	I-NP
O	2072	2074	of	of	IN	B-PP
O	2075	2093	neovascularization	neovascularization	NN	B-NP
O	2094	2096	in	in	IN	B-PP
O	2097	2100	the	the	DT	B-NP
B-Tissue	2101	2108	tissues	tissue	NNS	I-NP
O	2109	2120	surrounding	surround	VBG	B-VP
O	2121	2124	the	the	DT	B-NP
O	2125	2133	Matrigel	Matrigel	NNP	I-NP
O	2134	2144	containing	contain	VBG	I-NP
O	2145	2150	AdCMV	AdCMV	NN	I-NP
O	2150	2151	.	.	.	I-NP
O	2151	2158	VEGF165	VEGF165	NN	I-NP
O	2158	2159	,	,	,	O
O	2160	2167	whereas	whereas	IN	O
O	2168	2170	no	no	DT	B-NP
O	2171	2182	significant	significant	JJ	I-NP
O	2183	2195	angiogenesis	angiogenesis	NN	I-NP
O	2196	2199	was	be	VBD	B-VP
O	2200	2208	observed	observe	VBN	I-VP
O	2209	2211	in	in	IN	B-PP
O	2212	2220	response	response	NN	B-NP
O	2221	2223	to	to	TO	B-PP
O	2224	2229	AdCMV	AdCMV	NN	B-NP
O	2229	2230	.	.	.	O
O	2230	2234	beta	beta	NN	B-NP
O	2235	2238	gal	gal	JJ	B-ADJP
O	2238	2239	.	.	.	O

O	2240	2251	Furthermore	Furthermore	RB	B-ADVP
O	2251	2252	,	,	,	O
O	2253	2256	the	the	DT	B-NP
O	2257	2265	Matrigel	Matrigel	NNP	I-NP
O	2266	2271	plugs	plug	NNS	I-NP
O	2272	2276	with	with	IN	B-PP
O	2277	2282	AdCMV	AdCMV	NN	B-NP
O	2282	2283	.	.	.	O
O	2283	2290	VEGF165	VEGF165	NN	B-NP
O	2291	2303	demonstrated	demonstrate	VBD	B-VP
O	2304	2314	hemoglobin	hemoglobin	NN	B-NP
O	2315	2322	content	content	NN	I-NP
O	2323	2331	fourfold	fourfold	RB	B-ADJP
O	2332	2338	higher	high	JJR	I-ADJP
O	2339	2343	than	than	IN	B-PP
O	2344	2347	the	the	DT	B-NP
O	2348	2353	plugs	plug	NNS	I-NP
O	2354	2358	with	with	IN	B-PP
O	2359	2364	AdCMV	AdCMV	NN	B-NP
O	2364	2365	.	.	.	O
O	2365	2369	beta	beta	NN	B-NP
O	2370	2373	gal	gal	JJ	B-ADJP
O	2373	2374	.	.	.	O

O	2375	2383	Together	Together	RB	B-ADVP
O	2383	2384	,	,	,	O
O	2385	2390	these	these	DT	B-NP
O	2391	2393	in	in	FW	I-NP
O	2394	2399	vitro	vitro	FW	I-NP
O	2400	2403	and	and	CC	O
O	2404	2406	in	in	FW	B-NP
O	2407	2411	vivo	vivo	FW	I-NP
O	2412	2419	studies	study	NNS	I-NP
O	2420	2423	are	be	VBP	B-VP
O	2424	2434	consistent	consistent	JJ	B-ADJP
O	2435	2439	with	with	IN	B-PP
O	2440	2443	the	the	DT	B-NP
O	2444	2451	concept	concept	NN	I-NP
O	2452	2456	that	that	IN	B-SBAR
O	2457	2459	Ad	Ad	NN	B-NP
O	2460	2467	vectors	vector	NNS	I-NP
O	2468	2471	may	may	MD	B-VP
O	2472	2479	provide	provide	VB	I-VP
O	2480	2481	a	a	DT	B-NP
O	2482	2488	useful	useful	JJ	I-NP
O	2489	2497	strategy	strategy	NN	I-NP
O	2498	2501	for	for	IN	B-PP
O	2502	2511	efficient	efficient	JJ	B-NP
O	2512	2517	local	local	JJ	I-NP
O	2518	2526	delivery	delivery	NN	I-NP
O	2527	2529	of	of	IN	B-PP
O	2530	2537	VEGF165	VEGF165	NN	B-NP
O	2538	2540	in	in	IN	B-PP
O	2541	2544	the	the	DT	B-NP
O	2545	2554	treatment	treatment	NN	I-NP
O	2555	2557	of	of	IN	B-PP
O	2558	2566	ischemic	ischemic	JJ	B-NP
O	2567	2575	diseases	disease	NNS	I-NP
O	2575	2576	.	.	.	O

